The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated safety advice for finasteride and dutasteride, two medications commonly used to treat conditions such as benign prostatic hyperplasia (BPH) and male pattern baldness. The revised guidance significantly strengthens warnings about potential psychiatric and sexual dysfunction associated with finasteride, while also providing precautionary advice for dutasteride regarding similar risks.
Finasteride, available under brand names like Propecia and Proscar, has seen its product information updated to include more prominent warnings about mood alterations, including depression and suicidal thoughts, as well as persistent sexual dysfunction that may continue after stopping treatment. This includes reduced libido, erectile dysfunction, and ejaculation disorders. For dutasteride, often marketed as Avodart, the MHRA has introduced new precautionary advice, acknowledging the potential for similar adverse effects, although data for this specific drug is less extensive than for finasteride.
The decision to strengthen these warnings follows a comprehensive review of available safety data, including reports from patients and healthcare professionals. The MHRA emphasised the importance of ensuring that both prescribers and patients are fully informed about the potential risks before initiating or continuing treatment. Healthcare professionals are now advised to discuss these potential side effects in detail with patients, especially those with a history of psychiatric conditions or those who may be particularly vulnerable.
Patients currently taking finasteride or dutasteride who experience any new or worsening psychiatric symptoms, such as changes in mood, anxiety, or thoughts of self-harm, should seek medical advice immediately. Similarly, those experiencing persistent sexual dysfunction should consult their doctor. The MHRA also continues to encourage the reporting of suspected adverse drug reactions through its Yellow Card scheme, which helps to monitor the safety of medicines in the UK.
These medications work by inhibiting the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). DHT plays a key role in the development of BPH and male pattern baldness. While effective for their intended purposes, the balance of benefits and risks is a crucial consideration for both prescribers and patients.
The updated guidance underscores the MHRA's commitment to patient safety and its ongoing monitoring of medicines on the market. It reflects a proactive approach to communicating potential risks and ensuring that the public has access to the most current and accurate information regarding their treatments.
Source: MHRA